ImmixBio Releases And Ships Scaled-Up GMP Batches Of IMX-110 For Clinical Trial Patient Dosing
Immix Biopharma, Inc. (NASDAQ:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting
